Dopaminergic abnormalities in borderline essential hypertensive patients.

Area of Science:

• Biochemistry
• Cardiovascular Physiology
• Nephrology

Background:

• Borderline hypertension is associated with dopamine abnormalities.
• Altered dihydroxyphenylalanine (DOPA) metabolism may underlie these abnormalities.

Purpose of the Study:

• To investigate the relationship between DOPA metabolism and dopamine abnormalities in borderline hypertension.
• To assess the effects of DOPA administration on blood pressure, heart rate, and dopamine markers.

Main Methods:

• Measured blood pressure, pulse rate, plasma, and urine samples before and after oral DOPA administration (500 mg).
• Analyzed methoxytyramine, dopamine, dopamine sulfate, and DOPAC levels.
• Assessed DOPA load, natriuresis, and urinary sodium excretion.

Main Results:

• Borderline hypertensive patients exhibited higher baseline urinary methoxytyramine (dopamine release marker).
• DOPA induced greater systolic blood pressure reduction without reflex tachycardia in borderline hypertensives.
• Blunted plasma DOPA/dopamine increase but enhanced plasma dopamine sulfate/urinary DOPAC excretion was observed post-DOPA.
• DOPA elicited greater natriuresis in borderline hypertensives, independent of urinary dopamine excretion.

Conclusions:

• Data suggest increased basal exocytotic dopamine release in borderline hypertension.
• Accelerated neuronal and renal dopamine generation from DOPA occurs in these patients.
• DOPA-induced natriuresis in borderline hypertension may involve central sympathetic inhibition, reducing renal sympathetic tone.